Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...
Hosted on MSN
Is Recursion Pharmaceuticals a Meme Stock?
Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Marika Taylor currently receives funding from EPSRC, STFC, UK government deparments and the European Horizon programme. In 1980, Stephen Hawking gave his first lecture as Lucasian Professor at the ...
In 1980, Stephen Hawking gave his first lecture as Lucasian Professor at the University of Cambridge. The lecture was called "Is the end in sight for theoretical physics?" Forty-five years later, ...
Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...
RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...
The Permutation Generator lab currently requires people to create a recursive function to form an array of possible permutations of a string. But the way it wants that to happen seems to be very ...
Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...
June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...
Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback